Back to Search
Start Over
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective
- Source :
- Journal of Medical Economics. 24:291-298
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Considering clinical benefits of new combination therapies for metastatic renal-cell carcinoma (mRCC), this study aims to calculate the number needed to treat (NTT) and the cost of preventing an event (COPE) for pembrolizumab plus axitinib (P + A), and nivolumab plus ipilimumab (N + I) as first-line treatments, from the Brazilian private perspective. Overall survival (OS) and progression-free survival (PFS) data for intermediate- and poor-risk groups were obtained from KEYNOTE-426 and CHECKMATE-214 trials for P + A and N + I, respectively, versus sunitinib as mRCC first-line treatment. Considering a 12-month time horizon, 6 patients should be treated with P + A to prevent one death with sunitinib use, resulting in a COPE of 3,893,903 BRL. Using N + I, NNT for 12-month OS rate was 13 compared to sunitinib, with a COPE of 6,357,965 BRL. Regarding PFS data, NNT was also 6 when comparing P + A versus sunitinib, with an estimated COPE of 3,893,903 BRL. Estimated NNT was 20 comparing N + I and sunitinib, resulting in a COPE of 10,172,744 BRL. Cost differences between two treatment options, reached more than 6 million BRL for PFS, and 2 million BRL for OS. At the 12-month landmark, P + A suggests better economic scenario versus N + I as first-line mRCC treatment option for intermediate- and poor-risk groups, through an indirect comparison using sunitinib as a common comparator.
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Axitinib
Cost-Benefit Analysis
Ipilimumab
Pembrolizumab
Antibodies, Monoclonal, Humanized
urologic and male genital diseases
Severity of Illness Index
Young Adult
Antineoplastic Agents, Immunological
Renal cell carcinoma
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Sunitinib
medicine
Carcinoma
Humans
Carcinoma, Renal Cell
Aged
Aged, 80 and over
business.industry
Health Policy
Middle Aged
medicine.disease
Kidney Neoplasms
Progression-Free Survival
Models, Economic
Nivolumab
Number needed to treat
Health Resources
Adenocarcinoma
Female
Health Expenditures
business
Brazil
medicine.drug
Subjects
Details
- ISSN :
- 1941837X and 13696998
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- Journal of Medical Economics
- Accession number :
- edsair.doi.dedup.....6467fc4d5ea65a9ddee75546bc643c56